SAM
RVMD icon

Storebrand Asset Management’s Revolution Medicines RVMD Stock Holding History

Storebrand Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15M Buy
80,251
+26,886
+50% +$3.93M 0.04% 345
2026
Q1 		$5.19M Buy
+53,365
New +$5.39M 0.01% 473

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Storebrand Asset Management's RVMD Position: Q2 2026 in Review

Storebrand Asset Management increased its Revolution Medicines (RVMD) stake by 50% in Q2 2026, buying an estimated $3.93M and bringing the position to 80,251 shares worth $15M. The position accounts for 0.04% of the portfolio, ranked #345.

Storebrand Asset Management first reported a position in RVMD in Q1 2026 and has held it in 2 quarters since. 637 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Storebrand Asset Management held 80,251 shares of Revolution Medicines worth $15M as of Q2 2026.
  • Storebrand Asset Management bought 26,886 Revolution Medicines shares in Q2 2026, an estimated $3.93M.
  • Revolution Medicines made up 0.04% of Storebrand Asset Management's portfolio in Q2 2026, its #345 holding.
  • Storebrand Asset Management first reported a position in Revolution Medicines in Q1 2026 and has held it in 2 quarters since.
  • 637 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Storebrand Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.